Literature DB >> 21795795

Expression, crystallization and preliminary crystallographic study of the C-terminal half of nsp2 from SARS coronavirus.

Yuanyuan Li1, Zhilin Ren, Zehua Bao, Zhenhua Ming, Xuemei Li.   

Abstract

SARS coronavirus (SARS-CoV) is the aetiological agent of the highly infectious severe acute respiratory syndrome (SARS). To gain a better understanding of SARS-CoV replication and transcription proteins, a preliminary X-ray crystallographic study of the C-terminal domain of SARS-CoV nonstructural protein 2 (nsp2) is reported here. The C-terminal domain of SARS-CoV nsp2 was cloned, overexpressed, purified and crystallized using polyethylene glycol 5000 monomethyl ether as the precipitant; the crystals diffracted to 2.5 Å resolution. The crystals belonged to space group P6(5), with unit-cell parameters a=b=112.8, c=91.1 Å, α=β=90, γ=120°. One molecule is assumed to be present per asymmetric unit, which gives a Matthews coefficient of 2.89 Å3 Da(-1) and a solvent content of 56.2%.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21795795      PMCID: PMC3144797          DOI: 10.1107/S1744309111017829

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


Introduction

The 16 replicase/transcriptase proteins are crucial for the life cycle of SARS coronavirus (SARS-CoV), which is the causative agent of the highly infectious severe acute respiratory syndrome (SARS) that first appeared in late 2002 (Stadler et al., 2003 ▶) in Asia and subsequently spread worldwide. SARS-CoV belongs to the Coronaviridae family, with a single positive-stranded RNA genome of approximately 30 kb in length (Snijder et al., 2003 ▶). Since the SARS pandemic, the three-dimensional structures and functions of most of the replicase/transcriptase components, the nonstructural proteins (nsps), of SARS-CoV have been determined (Zhang et al., 2010 ▶; Yang et al., 2003 ▶; Almeida et al., 2006 ▶; Su et al., 2006 ▶; Xue et al., 2008 ▶; Xu et al., 2009 ▶). However, the structure and function of nsp2 from either SARS-CoV or related coronaviruses have remained uncharacterized. To date, the only reported crystal structure of a coronavirus nsp2 is that of the N-terminal domain of nsp2 from avian infectious bronchitis virus (IBV; Yang et al., 2009 ▶), a representive of the group 3 coronaviruses which is quite different from SARS-CoV nsp2 in primary sequence (with a sequence identity of less than 20%) and gene locus (with no nsp1 prior to nsp2 in IBV). Meanwhile, owing to a lack of research on nsp2-deficient viruses in animal models or on changes in host environment resulting from nsp2 deficiency, it has been widely accepted that nsp2 replicase proteins are dispensable for replication of mouse hepatitis virus (MHV) and SARS-CoV in cell culture owing to the detection of genomic and sub­genomic RNA production of nsp2-deficient viruses in cell culture (Graham et al., 2005 ▶). In order to help to elucidate the function(s) of this relatively large protein (70 and 65 kDa for SARS-CoV and MHV, respectively), we now report the expression, purification and crystallization of the C-­terminal half of nsp2 from SARS-CoV (referred to here as nsp2C; 58 kDa, corresponding to Lys112Gly638 of full-length SARS-CoV nsp2) as well as its preliminary structure determination by single-wavelength anomalous dispersion (SAD). Further analysis of the structure and function of nsp2 from SARS-CoV and other members of the coronavirus family should allow the elucidation of its precise function(s) involved in coronavirus pathogenesis on the basis of our crystal structure of SARS-CoV nsp2C.

Materials and methods

Cloning and expression

The coding sequence for SARS-CoV nsp2C was amplified by a standard PCR-based approach from the cDNA of SARS-CoV BJ01 strain (corresponding to Lys292Gly818 of pp1a replicative polyprotein, renumbered as Lys112Gly638). The PCR product was digested by BamHI and NotI and ligated into a pGEX-6p-1 expression vector (Pharmacia, New York, USA). The integrity of the construct was confirmed by DNA sequencing. SARS-CoV nsp2C was overexpressed in Escherichia coli strain BL21 (DE3) (Novagen, Merck, USA) as a GST (glutathione S-transferase) fusion protein. A seleno­methionyl (SeMet) derivative of nsp2C was prepared using the method of methionine-biosynthesis pathway inhibition. Expression of native and SeMet-derivative nsp2C was performed in 0.8 l Luria–Bertani medium and M9 medium, respectively, which was incubated at 310 K until the OD600 reached about 0.6. SARS-CoV nsp2C expression was induced by the addition of 0.5 mM isopropyl β-­d-1-thiogalactopyranoside (IPTG) for an additional 16 h at 289 K. For the preparation of soluble protein fractions, cells from the 0.8 l culture were pelleted, resuspended in 50 ml cold PBS as a lysis buffer containing 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, 1 mM DTT, 1 mM EDTA and 0.01% NP-40 pH 8.5 and lysed using a JN-3000 PLUS low-temperature ultrahigh-pressure cell disrupter (JNBIO, Guangzhou, People’s Republic of China).

Purification

The supernatant after centrifugation was collected and the fusion protein was purified by GST-glutathione affinity chromatography. The native and SeMet-derivative nsp2C-GST fusion proteins were further purified using the same procedure as follows: briefly, the bacterial cell lysate containing nsp2C protein was incubated with Glutathione-Sepharose 4B resin (GE Healthcare, USA) at 277 K. The GST tag was removed by overnight digestion at 277 K using GST-tagged PreScission protease (Amersham Biosciences) in 1×PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, 10% glycerol pH 8.5), leaving five additional residues (GPLGS) at the N-terminus. SARS-CoV nsp2C was further purified by Resource Q ion-exchange column chromatography (Amersham Biosciences, USA) at 291 K in 25 mM TrisHCl, 1 mM EDTA, 1 mM DTT, 0.01% NP-40 pH 8.5 with a 50–250 mM NaCl gradient and achieved high homogeneity; the protein purity was estimated to be about 90% by inspection of Coomassie-stained Tris–glycine SDS–PAGE gels (Fig. 1 ▶). All proteins were further characterized by MALDI–TOF mass spectrometry and incorporation of selenomethionine was also con­firmed by mass spectroscopy. Fractions containing pure protein were pooled and concentrated to 8 mg ml−1 for crystallization.
Figure 1

SDS–PAGE analysis of SARS-CoV nsp2C during purification. Proteins were analysed on 10% SDS–PAGE and stained with Coomassie Blue. Lane 1, molecular-weight markers (labelled in kDa). Lane 2, purified nsp2C after GST (glutathione S-­transferase) affinity column chromatography. The molecular weight of GST-nsp2C is 84 kDa, as indicated by a black arrow. Lane 3, purified nsp2C with approximately 90% purity after Resource Q ion-exchange column chromatography. The molecular weight of nsp2C is 58 kDa, as indicated by a black arrow.

Crystal growth, data collection and processing

Initial crystals were obtained via the hanging-drop vapour-diffusion method at 291 K by mixing 1 µl protein solution and 1 µl reservoir solution. Initial needle-shaped crystals of SARS-CoV nsp2C with extensive twinning appeared after one week in a condition from Hampton Research Crystal Screen. Crystals suitable for data collection with a length of up to 200 µm and variable thickness were grown using a reservoir solution consisting of 0.1 M Bis-Tris pH 6.5, 0.2 M NaCl, 20%(w/v) polyethylene glycol 5000 monomethyl ether (Fig. 2 ▶ a). Crystals of the SeMet derivative of nsp2C were obtained using the same conditions but grew to larger size (Fig. 2 ▶ b). Prior to data collection, the crystals were dehydrated for 2 h with reservoir solution plus 10% glycerol and were immediately soaked in cryoprotectant solution constituted of reservoir solution with 20% ethylene glycol followed by flash-freezing in liquid nitrogen.
Figure 2

SARS-CoV nsp2C crystals. (a) Native; (b) SeMet derivative.

The crystal-to-detector distance was set to 273.5 and 362.5 mm for native and SeMet-derivative nsp2C, respectively. All frames were collected at 93 K using a 0.8° oscillation angle with an exposure time of 2 s per frame. A total of 300 frames and 450 frames were collected for native and SeMet nsp2C, respectively. A native data set for nsp2C was collected to 2.7 Å resolution at a wavelength of 1.0 Å using a MAR 165 CCD detector on beamline BL17U at Shanghai Synchrotron Radiation Facility (SSRF; People’s Republic of China) and a single-wavelength anomalous dispersion (SAD; Terwilliger & Berendzen, 1999 ▶) data set for the SeMet derivative of nsp2C was collected to 3.5 Å resolution (Fig. 3 ▶) at a wavelength of 0.9787 Å using an ADSC Q270 CCD detector on beamline BL17A at Photon Factory (PF; Tsukuba, Japan). Data were processed, integrated and scaled using the HKL-2000 program package (Otwinowski & Minor, 1997 ▶). The initial phases were obtained using SHELX (Sheldrick, 2008 ▶) and PHENIX (Adams et al., 2002 ▶). The selenomethionine sites were located and interpretable maps were obtained. The phases were greatly improved after density-modification procedures using RESOLVE (Terwilliger, 2000 ▶, 2001 ▶) and DM in CCP4 (Winn et al., 2011 ▶). A summary of data collection and processing is shown in Table 1 ▶.
Figure 3

X-ray diffraction pattern from a crystal of native SARS-CoV nsp2C.

Table 1

Data-collection and processing statistics

Values in parentheses are for the highest resolution shell.

 Native nsp2CSeMet-derivative nsp2C
Data-collection statistics
 Unit-cell parameters (Å, °)a = b = 112.8, c = 91.1, α = β = 90, γ = 120a = b = 113.8, c = 91.2, α = β = 90, γ = 120
 Space groupP65P65
 Wavelength (Å)1.00.9787
 Resolution range (Å)50.0–2.7 (2.75–2.70) 50.0–3.5 (3.56–3.50)
 Mosaicity (°)0.71.1
 Solvent content (%)57.458.2
 Multiplicity12.2 (5.1)16.2 (7.1)
Data processing
 No. of observed reflections220979138180
 No. of unique reflections180448556
 Completeness (%)99.5 (98.5)100.0 (99.5)
 〈I/σ(I)〉32.6 (2.6)21.8 (2.7)
Rmerge (%)13.1 (65.8)16.0 (61.3)

R merge = , where 〈I(hkl)〉 is the mean of the observations I (hkl) of reflection hkl.

Results and discussion

The crystal of nsp2C belonged to space group P65, which was identified after we had obtained the initial phases using SHELX and the SeMet-nsp2C data set. The unit-cell parameters were a = b = 112.8, c = 91.1 Å, α = β = 90, γ = 120° and there was only one molecule per asymmetric unit, corresponding to a calculated Matthews coefficient of 2.89 Å3 Da−1 and a solvent content of 57.4% (Matthews, 1968 ▶). The anomalous data provided four clear selenium sites. The initial phases were improved by solvent flattening (DM; Winn et al., 2011 ▶) and the electron-density map allowed us to trace most of the main-chain residues of SARS-CoV nsp2C. After several iterations of density modification using both the DM and SHARP programs, the phases were greatly improved, with most of the amino-acid residues being clearly interpretable (Fig. 4 ▶); exceptions were the C-terminal end, which consists mostly of loop and coil, as well as electron density in some regions owing to flexibility. Further model building and refinement of the structure of SARS-CoV nsp2C is in progress. The successful crystallization of nsp2C from SARS-CoV to give crystals that were suitable for structure determination should allow us to answer many of the fundamental questions that remain unclear about the role(s) of nsp2 in the regulation of coronavirus pathogenesis.
Figure 4

A 1.5σ-weighted 2F o − F c electron-density map of SARS-CoV nsp2C.

  17 in total

1.  NMR assignment of the SARS-CoV protein nsp1.

Authors:  M S Almeida; M A Johnson; K Wüthrich
Journal:  J Biomol NMR       Date:  2006       Impact factor: 2.835

2.  Dodecamer structure of severe acute respiratory syndrome coronavirus nonstructural protein nsp10.

Authors:  Dan Su; Zhiyong Lou; Fei Sun; Yujia Zhai; Haitao Yang; Rongguang Zhang; Andrzej Joachimiak; Xuejun C Zhang; Mark Bartlam; Zihe Rao
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

3.  Solvent content of protein crystals.

Authors:  B W Matthews
Journal:  J Mol Biol       Date:  1968-04-28       Impact factor: 5.469

4.  The nsp2 replicase proteins of murine hepatitis virus and severe acute respiratory syndrome coronavirus are dispensable for viral replication.

Authors:  Rachel L Graham; Amy C Sims; Sarah M Brockway; Ralph S Baric; Mark R Denison
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Automated MAD and MIR structure solution.

Authors:  T C Terwilliger; J Berendzen
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-04

6.  Map-likelihood phasing.

Authors:  T C Terwilliger
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2001-11-21

7.  Overview of the CCP4 suite and current developments.

Authors:  Martyn D Winn; Charles C Ballard; Kevin D Cowtan; Eleanor J Dodson; Paul Emsley; Phil R Evans; Ronan M Keegan; Eugene B Krissinel; Andrew G W Leslie; Airlie McCoy; Stuart J McNicholas; Garib N Murshudov; Navraj S Pannu; Elizabeth A Potterton; Harold R Powell; Randy J Read; Alexei Vagin; Keith S Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

8.  Expression, crystallization and preliminary X-ray diffraction analysis of the N-terminal domain of nsp2 from avian infectious bronchitis virus.

Authors:  Anqi Yang; Lei Wei; Weiran Zhao; Yuanyuan Xu; Zihe Rao
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-07-25

Review 9.  SARS--beginning to understand a new virus.

Authors:  Konrad Stadler; Vega Masignani; Markus Eickmann; Stephan Becker; Sergio Abrignani; Hans-Dieter Klenk; Rino Rappuoli
Journal:  Nat Rev Microbiol       Date:  2003-12       Impact factor: 60.633

10.  Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage.

Authors:  Eric J Snijder; Peter J Bredenbeek; Jessika C Dobbe; Volker Thiel; John Ziebuhr; Leo L M Poon; Yi Guan; Mikhail Rozanov; Willy J M Spaan; Alexander E Gorbalenya
Journal:  J Mol Biol       Date:  2003-08-29       Impact factor: 5.469

View more
  1 in total

Review 1.  Atlas of coronavirus replicase structure.

Authors:  Benjamin W Neuman; Peter Chamberlain; Fern Bowden; Jeremiah Joseph
Journal:  Virus Res       Date:  2013-12-16       Impact factor: 3.303

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.